P. Breitfeld

Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.

P. Houghton, S. Donaldson, A. Pappo, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group.

A. Pappo, D. Hawkins, S. Qualman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.

James R. Anderson, D. Hawkins, W. Meyer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience.

D. Rodeberg, W. Meyer, S. Qualman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.